Chronic myeloid leukemia: reminiscences and dreams

Simple item page
dc.contributor.authorMughal, T.
dc.contributor.authorRadich, J.
dc.contributor.authorDeininger, M.
dc.contributor.authorApperley, J.
dc.contributor.authorHughes, T.
dc.contributor.authorHarrison, C.
dc.contributor.authorGambacorti-Passerini, C.
dc.contributor.authorSaglio, G.
dc.contributor.authorCortes, J.
dc.contributor.authorDaley, G.
dc.date.issued2016
dc.description.abstractWith the deaths of Janet Rowley and John Goldman in December 2013, the world lost two pioneers in the field of chronic myeloid leukemia. In 1973, Janet Rowley, unraveled the cytogenetic anatomy of the Philadelphia chromosome, which subsequently led to the identification of the BCR-ABL1 fusion gene and its principal pathogenetic role in the development of chronic myeloid leukemia. This work was also of major importance to support the idea that cytogenetic changes were drivers of leukemogenesis. John Goldman originally made seminal contributions to the use of autologous and allogeneic stem cell transplantation from the late 1970s onwards. Then, in collaboration with Brian Druker, he led efforts to develop ABL1 tyrosine kinase inhibitors for the treatment of patients with chronic myeloid leukemia in the late 1990s. He also led the global efforts to develop and harmonize methodology for molecular monitoring, and was an indefatigable organizer of international conferences. These conferences brought together clinicians and scientists, and accelerated the adoption of new therapies. The abundance of praise, tributes and testimonies expressed by many serve to illustrate the indelible impressions these two passionate and affable scholars made on so many people's lives. This tribute provides an outline of the remarkable story of chronic myeloid leukemia, and in writing it, it is clear that the historical triumph of biomedical science over this leukemia cannot be considered without appreciating the work of both Janet Rowley and John Goldman.
dc.description.statementofresponsibilityTariq I. Mughal, Jerald P. Radich, Michael W. Deininger, Jane F. Apperley, Timothy P. Hughes, Christine J. Harrison, Carlo Gambacorti-Passerini, Giuseppe Saglio, Jorge Cortes, George Q. Daley
dc.identifier.citationHaematologica, 2016; 101(5):541-558
dc.identifier.doi10.3324/haematol.2015.139337
dc.identifier.issn0390-6078
dc.identifier.issn1592-8721
dc.identifier.orcidHughes, T. [0000-0002-0910-3730] [0000-0002-7990-4509]
dc.identifier.urihttp://hdl.handle.net/2440/112926
dc.language.isoen
dc.publisherFondazione Ferrata Storti
dc.rights©2016 Ferrata Storti Foundation. Material published in Haematologica is covered by copyright. All rights reserved to the Ferrata Storti Foundation. Copies of articles are allowed for personal or internal use. Permission in writing from the publisher is required for any other use.
dc.source.urihttps://doi.org/10.3324/haematol.2015.139337
dc.subjectPhiladelphia Chromosome
dc.subjectHumans
dc.subjectFusion Proteins, bcr-abl
dc.subjectAntineoplastic Agents
dc.subjectProtein Kinase Inhibitors
dc.subjectPrognosis
dc.subjectCytogenetic Analysis
dc.subjectMutation
dc.subjectResearch
dc.subjectHistory, 20th Century
dc.subjectLeukemia, Myelogenous, Chronic, BCR-ABL Positive
dc.subjectMolecular Targeted Therapy
dc.titleChronic myeloid leukemia: reminiscences and dreams
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications